NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market that its second-quarter revenues increased 6 percent year over year as sales volume for its OVA1 flagship diagnostic test rose by the same percentage.

The Austin, Texas-based molecular diagnostics firm brought in total revenues of $321,000 for the three months ended June 30, compared to $304,000 for the second quarter of 2011. Its license revenues, collected from clinical lab firm Quest Diagnostics, were static year over year at $113,000, while its product revenues increased to $208,000 from $191,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.